Reply Academic Article uri icon

  • Overview
  • Identity
  • View All


  • Dr. Miller's point is well-taken. It is because there has been a lack of existing data about differential efficacy among NSAIDs that we took the approach of grouping them into classes, since it is a common clinical question as to whether one class of NSAID is better than another for gout flares in particular(2-5). We did this to better understand whether there were any specific class differences since this sort of study has never been done specifically in gout flares.


  • Brignardello, Romina
  • Zeng, Linan
  • Neogi, Tuhina
  • Fitzgerald, John D
  • Dalbeth, Nicola
  • Mikuls, Ted R
  • Brignardello‐Petersen, Romina

publication date

  • July 20, 2021